Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback